|
Market Closed -
Euronext Paris
11:55:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.3850 EUR | -1.16% |
|
+0.65% | +29.19% |
| 08-27 | The FDA will issue its decision on Nicox's NCX 470 by the end of next April |  |
| 08-27 | US FDA to Complete Nicox's Glaucoma Drug Review by April 2027 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NICOX SA | Specialty & Advanced Pharmaceuticals | -1.16% | +0.65% | +29.19% | +3.91% | -88.42% | 39.38M |  | | |
- Stock Market
- Stocks
- ALCOX Stock
- Charts Nicox SA
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
